CD274 and non-small cell lung carcinoma: Conversely, tumor PD-L1 expression ≥90% was associated with longer OS in multivariable analyses of a large cohort of patients with metastatic NSCLC and PD-L1 expression ≥50% treated with first-line pembrolizumab monotherapy (23).